LLY vs PFE: Which Is the Better Buy?
Side-by-side comparison of Eli Lilly and Company and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-05.
Eli Lilly and Company · Healthcare
$934.34
+17.6% upside to fair value
Grade B
High Quality
VS
Pfizer Inc. · Healthcare
$26.33
+28.6% upside to fair value
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+28.6%).
PFE trades at a lower forward P/E
(19.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
LLY |
PFE |
| Current Price |
$934.34 |
$26.33 |
| Fair Value Estimate |
$1,098.43 |
$33.85 |
| Upside to Fair Value |
+17.6%
|
+28.6%
|
| Market Cap |
$882.8B |
$149.8B |
| Forward P/E |
33.1x
|
19.3x
|
| EV / EBITDA |
27.9x
|
12.9x
|
| Price / Sales |
12.2x
|
2.4x
|
| Price / FCF |
65.0x
|
16.5x
|
| Revenue Growth YoY |
+55.5%
|
-1.2%
|
| Gross Margin |
82.7%
|
70.3%
|
| Operating Margin |
46.3%
|
24.7%
|
| Return on Equity |
101.3%
|
8.7%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
1.54%
|
6.06%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Eli Lilly and Company is a leading global pharmaceutical firm with a dominant position in the diabetes and obesity markets, driven by its blockbuster GLP-1 drugs Mounjaro and Zepbound which generated $36.5 billion in FY2025. The company reported $65.2 billion in total revenue for 2025, making it the top pharma by revenue globally. It exhibits high business quality with a durable competitive moat …
Pfizer Inc. is a leading global pharmaceutical company specializing in drug manufacturing with a strong presence in vaccines, oncology, and primary care. The company benefits from a seasoned leadership team under CEO Albert Bourla, who has driven a strategic transformation focusing on science-driven innovation and portfolio optimization. Despite a high gross margin of 70.3% and solid operating ma…
Accumulation Zones
| Metric |
LLY |
PFE |
| Zone Low |
$823.82 |
$25.39 |
| Zone High |
$933.67 |
$28.77 |
| In Buy Zone? |
No
|
Yes
|